Innovation For Life
Defeating Pain, Controlling Inflammation
Our Company We are a pre-clinical stage pharmaceutical company using our proprietary NCE to treat acute and chronic inflammation. We will offer our products for licensing post Ph II studies in high unmet need indications.
Our Science
Our NCE target the endocannabinoid and cyclooxygenase pathways. Our technology allows intravenous, topical and intranasal delivery.
Our Indications
Our NCE will benefit patients suffering the pain and inflammation of dry eye syndrome, and those experiencing pain after surgery.
NEWS
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
TALLC Innovation in Vision
© TALLC Inc. 2020